Targets: MTX5 & MTX3

Oncomatryx is developing precision drugs that target membrane proteins in stromal cells.


  • Membrane glycoprotein of cancer-associated fibroblasts
    Target MTX5 MTX3
  • Internalization capability
  • Peritumoral stroma overexpression in >90% carcinomas
  • No MTX5 gene expression has been reported in healthy tissues, with the exception of low-level expression in adipocytes, smooth muscle, bone marrow and uterus
  • Extracellular matrix remodeling, tumor growth and metastasis
  • Tumor immune system suppression. Depletion of MTX5-expressing cells in pancreatic cancer allowed TNF-α and IFN-ƴ immunological control of tumor growth. Depletion of MTX5-expressing CAFs overcame the lack of anti-tumor response of PD-L1 antibodies, and thus synergizing with anti-PD-L1 immunotherapy in pancreatic cancer.
  • Previous approaches blocking MTX5, have failed in Phase II due to lack of efficacy. Oncomatryx approach is not aimed at blocking MTX5, but at using MTX5 as a CAF-specific internalization vehicle for cytotoxic molecules.



  • Membrane protein of endothelial cells
  • Internalization capability
  • TGF-beta receptor pathway
  • Overexpression in tumor microvasculature cells
  • Low levels of MTX3 gene expression have been reported in cardiomyocytes and lung
  • Optimal accessibility from blood
  • Angiogenesis and neovascularization in different types of cancer

By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.